Maas BiolAB Presents to Investor Forum
Burlingame, CA ---May 7, 2007--- Maas BiolAB presented at the 2007 Life Sciences Investor Forum, part of the California Equity Capital Symposium Series, held at the San Francisco Airport Marriott on April 25, 2007. Maas was one of fourteen companies selected to present their business cases before qualified California life sciences investors. The Maas presentation by Michael Vickers focused on the development of Mitogard™ for the treatment of amyotrophic lateral sclerosis (ALS). The Life Sciences Investor Forum was sponsored by Technology Ventures Corporation as well as Claremont Creek Ventures.
Maas BiolAB is a privately held neuropharmaceutical corporation based in Albuquerque, NM, USA developing the proprietary cyclosporin formulation Mitogard™ for the brain diseases of Alzheimer’s, Parkinson’s, and Huntington’s and amyotrophic lateral sclerosis (ALS). NeuroPharma AB is a Maas corporate and research partner developing NeuroSTAT™, a proprietary non-toxic intravenous cyclosporin formula to treat traumatic brain injury, spinal cord injury and stroke. NeuroPharma AB is located in the Medicon Valley biotechnology center of southern Sweden, and has research affiliation with the laboratories of the Wallenberg Neuroscience Center, Lund University. For more information please visit www.maasbiolab.com.
Technology Ventures Corp. Incubator
1155 University Blvd. SE
Albuquerque, NM 87106